Loading stock data…
Candel Therapeutics (CADL)
$10.36+0.57 (+5.82%)
Market ClosedLast close Jun 29
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Candel Therapeutics, Inc. in the Healthcare sector is trading at $10.36 with a market capitalization of $591M. Wall Street consensus targets $20.29 (7 analysts), implying a +95.8% move over the next 12 months. The stock is currently near its 52-week high of $10.38, remaining 71.8% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals. The Whystock Score of 80/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +95.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$16.26M↓ | -$15.66M↓ | -$13.21M↓ | -$11.18M↓ | -$8.13M |
| Net Income | -$8.86M↑ | -$29.50M↓ | -$11.27M↓ | -$4.80M↓ | $7.38M |
Peer Comparison
JNJUNHPFE
Fundamentals
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$590.92M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-39.43%
Volume
Today's trading volume
1.47M
Recent News
Candel Therapeutics Designates Mark Sims as CCO
By Karen Roman Candel Therapeutics, Inc. (Nasdaq: CADL) said it appointed Mark Sims as Chief Commercial Officer effective July 6, 2026, having previously served at AstraZeneca as Vice President and Global Franchise Head, where he directed the commercial strategy for one of the company’s largest business franchises. Mr. Sims will lead the commercial strategy and […] The post Candel Therapeutics Designates Mark Sims as CCO appeared first on ExecEdge.
CADL Stock Heads For Best Week In A Month – Here’s Why Retail Is Bullish
Candel Therapeutics Phase 3 prostate cancer trial showed a higher disease-free survival rate.
Candel Therapeutics Eyes Year-End BLA After Strong Prostate Cancer Data
Candel Therapeutics (NASDAQ:CADL) Chief Executive Officer Dr. Paul Peter Tak said the company remains focused on advancing its viral immunotherapy programs following newly presented prostate cancer data and as it prepares for a planned biologics license application submission by the end of the year.
Wall Street Analysts Believe Candel Therapeutics (CADL) Could Rally 148.48%: Here's is How to Trade
The mean of analysts' price targets for Candel Therapeutics (CADL) points to a 148.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Candel Therapeutics teams up with EVERSANA to prep for prostate cancer drug launch
Candel Therapeutics Inc (NASDAQ:CADL), a clinical-stage biopharmaceutical company developing multimodal immunotherapies for cancer patients, has signed a commercialization agreement with EVERSANA, a global commercialization services provider, to gear up for the potential US launch of...